Infection: Proof of principle for effectiveness of a gonorrhoea vaccine
- PMID: 28858332
- PMCID: PMC5735823
- DOI: 10.1038/nrurol.2017.139
Infection: Proof of principle for effectiveness of a gonorrhoea vaccine
Abstract
Antimicrobial resistance in Neisseria gonorrhoeae compromises gonorrhoea treatment globally and vaccines might be the only sustainable solution for gonorrhoea control. A new study for the first time provides a proof of principle for protection with ~31% effectiveness against gonorrhoea, owing to cross-protection by the outer membrane vesicle Neisseria meningitidis serogroup B vaccine (MeNZB).
Conflict of interest statement
The authors declare no competing interests.
Comment on
-
Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study.Lancet. 2017 Sep 30;390(10102):1603-1610. doi: 10.1016/S0140-6736(17)31449-6. Epub 2017 Jul 10. Lancet. 2017. PMID: 28705462 Clinical Trial.
References
-
- World Health Organization. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. WHO; 2012. http://www.who.int/reproductivehealth/publications/rtis/9789241503501/en/
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical